perindopril arginine / Generic mfg. - LARVOL DELTA

Immune cell uptake of glycinated nanoparticles conjugated to anti-fibrotic peptides enables their prolonged activity and oral administration. (PubMed, J Biomed Sci) - "The conjugation of RXFP1-binding peptides to glycine-functionalised biodegradable SPIONs allowed for their circumnavigation of the gut, and prolonged activity as orally administered therapies. These findings have significant ramifications for the oral administration of peptide therapies in general."

Journal • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Immunology • AVEN

A systematic review of commencing full dose antihypertensives in newly diagnosed hypertension. (PubMed, Blood Press) - "The review assessed commonly used antihypertensive drugs (perindopril 8 mg, ramipril 10 mg, amlodipine 10 mg, losartan 100 mg, irbesartan 300 mg, candesartan 16 mg and candesartan 32 mg) compared to low starting doses or placebo RCTs. The review indicates that initiating full dose antihypertensives for essential hypertension may be beneficial and safe. The available data are limited and further RCTs are required to assess this in specific patient groups to assess safety and efficacy."

Journal • Review • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Dementia • Hypertension • Nephrology • Renal Disease

Diversified, endothelial cell-dependent cancer cell response to hypertensive serum modified by antihypertensive drugs. (PubMed, Sci Rep) - "Serum was collected from hypertensive patients treated with amlodipine, nebivolol, and perindopril for 6 weeks, alongside samples from healthy individuals. In summary, our study demonstrates that antihypertensive therapy, especially with nebivolol, potentially reverses hypertension-induced changes that exacerbate the cancer-promoting phenotype of endothelial cells. This suggests that beyond controlling blood pressure, antihypertensive treatments may also play a role in modulating cancer progression."

Journal • Cardiovascular • Hypertension • Oncology • Pulmonary Arterial Hypertension • ANGPT1 • CDH1 • CXCL1 • CXCL12 • CXCL8 • OCLN • TGFB1

Effects of Inhibitors of the Activity of the Circulating Renin-Angiotensin System on the Growth and Proliferation of Endometrial Cancer Cells. (PubMed, Int J Mol Sci) - "We then determined the effects of drugs that inhibit the action of renin (VTP-27999 and aliskiren) or angiotensin-converting enzyme (perindoprilat) or block the angiotensin II type 1 receptor (losartan and telmisartan). RAS inhibitors were most effective in Ishikawa cells, which had the highest levels of RAS expression. Therefore, levels of RAS expression in endometrial cancers might indicate the potential efficacy of RAS drugs."

Journal • Endometrial Cancer • Oncology • Solid Tumor

Systemic Solutions Influencing Physicians' Prescription Behavior Leading to Savings in the Reimbursement Budget in European Countries: A Systematic Literature Review (ISPOR-EU 2025) - "The number of INN prescriptions for antihypertensive drugs (bisaprolol/ perindopril) increased from 2,1% in 2019 to 92,3% in 2021 and for oral anticoagulants from 3,1% in 2018 to 79,7% in 2022... Introducing appropriate reimbursement regulations can lead to better control over pharmaceutical spending and improved allocation of healthcare resources."

Reimbursement • Review • US reimbursement

Systemic Solutions Influencing Physicians' Prescription Behavior Leading to Savings in the Reimbursement Budget in European Countries: A Systematic Literature Review (ISPOR-EU 2025) - "The number of INN prescriptions for antihypertensive drugs (bisaprolol/ perindopril) increased from 2,1% in 2019 to 92,3% in 2021 and for oral anticoagulants from 3,1% in 2018 to 79,7% in 2022... Introducing appropriate reimbursement regulations can lead to better control over pharmaceutical spending and improved allocation of healthcare resources."

Reimbursement • Review • US reimbursement

DiffErenCes in AntihypertenSive Drug Blood Levels in Patients with HypertensiON (DECISION): A prospective study comparing pharmacokinetics and pharmacodynamics of perindopril in younger and older patients. (PubMed, Blood Press) - "Older adults exhibited higher perindoprilat exposure than younger adults, alongside an exploratory, non-significant trend toward greater systolic BP reduction. Given the limited sample size, no causal inference can be drawn from our data; nevertheless, these findings support consideration of age-related factors and individualised dosing in hypertension management."

Journal • PK/PD data • Cardiovascular • Hypertension

Risk of liver dysfunction with ACE inhibitors based on real-world data from the MID-NET® in Japan. (PubMed, Hypertens Res) - "To compare the risk of liver dysfunction between the control group (enalapril maleate) and each exposure group, a pairwise Cox proportional hazards model was employed to estimate the hazard ratio (HR) adjusted by inverse probability weighting based on the high-dimensional propensity score...Compared with the control group, the HRs (95% confidence interval) were 1.37(0.79-2.38) for captopril, 0.71(0.33-1.54) for alacepril, 0.72(0.55-0.93) for imidapril hydrochloride, 1.08(0.86-1.34) for perindopril erbumine, and 0.69(0.52-0.91) for lisinopril hydrate. The risk of liver dysfunction with ACE inhibitors is unlikely to be a class-effect. Although continuous safety monitoring is necessary for promoting proper use of ACE inhibitors, the results indicate that no additional safety measures are currently required for ACE inhibitors that do not carry a liver dysfunction-related warning in Japan."

Journal • Real-world evidence • Cardiovascular • Hepatology • Hypertension • Liver Failure

Comparative Study on the Neuroprotective Effects of Perindopril and Benazepril in Experimentally-induced Chronic Mild Stress in Rats. (PubMed, J Neuroimmune Pharmacol) - "This study is among the first to highlight the antidepressant potential of benazepril, a non-centrally acting ACE inhibitor, and provides novel insights into its comparative efficacy against perindopril. These results collectively emphasize the broader therapeutic potential of ACE inhibitors in treating depression and underscore the need for further research to fully explore their underlying mechanisms and diverse applications in psychiatric disorders."

Clinical • Journal • Preclinical • CNS Disorders • Depression • Inflammation • Mental Retardation • Mood Disorders • Psychiatry

Retraction Note. (PubMed, Eur Rev Med Pharmacol Sci) - "Perindopril inhibits myocardial apoptosis in mice with acute myocardial infarction through TLR4/NF-κB pathway...SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway...Natural killer cell-derived exosome-entrapped paclitaxel can enhance its anti-tumor effect...Antidiabetic drug metformin mitigates ovarian cancer SKOV3 cell growth by triggering G2/M cell cycle arrest and inhibition of m-TOR/PI3K/Akt signaling pathway...These articles have been retracted. The Publisher apologizes for any inconvenience this may cause."

IO biomarker • Journal • Alzheimer's Disease • Ankylosing Spondylitis • Brain Cancer • Breast Cancer • Cardiovascular • CNS Disorders • Dementia • Diabetic Nephropathy • Genito-urinary Cancer • Glioblastoma • Hepatocellular Cancer • Immunology • Inflammatory Arthritis • Liver Cancer • Lung Cancer • Myocardial Infarction • Nephrology • Non Small Cell Lung Cancer • Oncology • Ophthalmology • Ovarian Cancer • Renal Cell Carcinoma • Renal Disease • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Solid Tumor • BCL2 • CD151 • CDH1 • IGF1 • MIR139 • MIR155 • miR-185 • MIR221 • MIR490 • MMP2 • MMP9 • SNHG14 • SNHG7 • TGFB1 • UCA1

Comparative Efficacy And Safety Of Cardioprotective Drugs In Patients With Breast Cancer Undergoing Chemotherapy: A Frequentist Network Meta-analysis (HFSA 2025) - "Bisoprolol (MD: -3.03%, SUCRA: 0.5561, P=0.0190) and Candesartan (MD: -2.93%, SUCRA: 0.5524, P=0.0013) showed moderate yet significant benefits. Spironolactone, Nebivolol, and Lisinopril+Bisoprolol showed significant protective effects on LVEF in breast cancer patients receiving chemotherapy. Spironolactone was identified as the most effective option, whereas Carvedilol, Metoprolol, and Perindopril had limited benefit. These findings support using Spironolactone, Nebivolol, or combination therapies for cardioprotection during chemotherapy."

Retrospective data • Breast Cancer • Oncology • Solid Tumor

Case-based evaluation of a digital timeline tool for drug causality assessment in skin eruptions (EADV 2025) - " The digital timeline identified five drugs with temporally compatible exposure: rilmenidine, diosmectite, enoxaparin, lercanidipine, and the combination perindopril/indapamide. This case highlights the potential benefit of digital tools in standardizing the visualization of medication histories for suspected drug-induced skin reactions. Digitalization of causality assessment processes may enhance diagnostic accuracy and workflow efficiency in complex clinical scenarios."

Clinical • Immunology

Results of a Single-Center Prospective Observational Study: How to Take Care of the Heart of a Cancer Patient. (PubMed, Kardiologiia) - "The main group consisted of 84 patients at high and very high risk of cardiotoxicity who were prescribed cardioprotective therapy, including a fixed combination of the angiotensin-converting enzyme inhibitor (ACEI) perindopril and the beta-blocker bisoprolol with trimetazidine. Thus, by the final visit, 13.1% of patients had died in the main group while in the comparison group, mortality was almost two times higher and reached 22.7%. Conclusion    The study demonstrated clinical effectiveness of the cardioprotective therapy in cancer patients at high and very high risk of cardiotoxicity. The patients who did not receive the primary drug prevention of cardiovascular toxicity had a statistically significant impairment of the LV systolic function, an increased number of developed complications, and a higher mortality."

Journal • Observational data • Cardiovascular • Oncology • MPO

Cardioprotective effect of Yiqi Huoxue decoction on post-myocardial infarction injury mediated by Ca2+ flux through MAMs. (PubMed, Front Cardiovasc Med) - "in vivo, Rats were randomly divided into Sham, Model, YQHX (8.2 g/kg) and Perindopril (10 mg/kg) groups...YQHX also restored MAMs morphology, decreased mPTP opening and Ca2+ levels, and reversed GRP75 downregulation blocked by MKT-077 under oxygen-glucose deprivation. YQHX exerts cardioprotection against hypoxia by regulating Ca2+ homeostasis and preserving MAMs structure, function, and associated protein expression."

Journal • Cardiovascular • Myocardial Infarction • Myocardial Ischemia • HSPA9 • MFN2 • PPIF • VDAC1

Molecular basis of domain-specific angiotensin I-converting enzyme inhibition by the antihypertensive drugs enalaprilat, ramiprilat, trandolaprilat, quinaprilat and perindoprilat. (PubMed, FEBS J) - "None of the binding modes of the inhibitors extend beyond the S1-S2' subsites to make use of the unique nACE/cACE residues that have been shown to influence domain selectivity. These findings supplement our understanding of ACE inhibition by the clinically used ACE inhibitors, and this information should be useful in the future design of more domain-selective inhibitors for the treatment of hypertension and cardiovascular diseases."

Journal • Cardiovascular • Fibrosis • Hypertension • Immunology

Amlodipine and perindopril modulate miR-874-3p expression to regulate ferroptosis-linked LPCAT3/LACS4/GPX4 Axis and gut dysbiosis in metabolic-associated steatohepatitis. (PubMed, Int Immunopharmacol) - "Amlodipine and perindopril, particularly in combination, effectively modulate the miR-874-3p/LPCAT3/LACS4/GPX4 axis to address ferroptosis and gut dysfunction in MASH, offering promising therapeutic avenues."

Journal • Fibrosis • Gastrointestinal Disorder • Hematological Disorders • Hepatology • Immunology • Inflammation • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • CASP3 • GPX4 • IL6 • LPCAT3 • OCLN • TGFB1

Study of the efficacy and safety of sacubitril-valsartan versus perindopril in the treatment of patients with heart failure (ChiCTR) - P4 | N=220 | Not yet recruiting | Sponsor: The Affiliated Hospital of Yunnan University; The Affiliated Hospital of Yunnan University

New P4 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

The effect of Sacubitril/valsartan On Long-term oUtcomes in nonparoxysmal atrial fibrillation paTients wIth adverse left atrial remOdeling after ablatioN (SOLUTION trial) (ChiCTR) - P4 | N=210 | Recruiting | Sponsor: Wujin Hospital Affiliated with Jiangsu University; Wujin Hospital Affiliated with Jiangsu University

New P4 trial • Atrial Fibrillation • Cardiovascular

Myxedema coma following urgent subdural hematoma drainage surgery: a case report (Euroanaesthesia 2025) - "Myxedema coma is a rare and severe cause specially in older adults with thyroid dysfunction.1,2 This report highlights a case of myxedema coma in the postoperative of an urgent subdural hematoma (SDH) drainage.Case Report: A 92-years-old women with medical history of hypertension and hyperthiroidism, medicated with lanzoprazol 15 mg id, furosemide 40 mg id, perindopril 5 mg id, levetiracetam 500mg 3id, atorvastatina 10 mg id and methimazol 5 mg id, presented to the hospital with altered mental status scoring 9 to 14 in the Glasgow Coma Scale (GCS)...The laboratory tests revealed a severe hypothyroidism (free thyroxine 0,11 ng/dl and thyroid-stimulating hormone 109 uU/ml).After urgent endocrinological consultation the patient begun 200 mcg of intravenous levothyroxine followed by 25mcg orally with a rapid and significant improvement...Its diagnosis requires a higher degree of suspicion. Timely intervention and endocrinological collaboration are essential to reduce..."

Case report • Clinical • Surgery • Anesthesia • Cardiovascular • CNS Disorders • Endocrine Disorders • Hypertension

Case Report: VV-ECMO as a bridge to recovery from ACE inhibitor induced post-obstructive negative pressure pulmonary edema. (PubMed, Front Med (Lausanne)) - "This case underscores the critical role of VV-ECMO as a bridge to recovery from severe NPPE. It also highlights the need to raise clinicians' awareness of the potential life-threatening side effects of the commonly used antihypertensive drug perindopril."

Journal • Cardiovascular • Respiratory Diseases

Xinyang Tablets ameliorate ventricular remodeling in heart failure via FTO/m6A signaling pathway (PubMed, Zhongguo Zhong Yao Za Zhi) - "Mice were randomized into sham, model, XYP(low, medium, and high doses), and positive control( perindopril) groups(n= 10)...Furthermore, FTO knockdown reversed the protective effects of XYP-containing serum on Ang Ⅱ-induced cardiomyocyte hypertrophy. In conclusion, XYP may ameliorate ventricular remodeling by regulating the FTO/m6A axis, thereby inhibiting the activation of the PI3K/Akt signaling pathway."

Journal • Cardiovascular • Congestive Heart Failure • Fibrosis • Genetic Disorders • Heart Failure • Immunology • Obesity • FTO

SARTAN-AD: Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients (clinicaltrials.gov) - P2 | N=23 | Terminated | Sponsor: Sunnybrook Health Sciences Centre | N=150 ➔ 23 | Trial completion date: Sep 2023 ➔ Feb 2025 | Recruiting ➔ Terminated | Trial primary completion date: Sep 2023 ➔ Feb 2025; Lack of recruitment.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Alzheimer's Disease • CNS Disorders

Stage-dependent proteomic alterations in aqueous humor of diabetic retinopathy patients based on data-independent acquisition and parallel reaction monitoring. (PubMed, J Transl Med) - "This study established a comprehensive AH proteomic signature of DR progression, offering insights into the pathogenesis of DR and highlighting potential biomarkers and novel therapeutic targets."

Biomarker • Journal • Cataract • Diabetes • Diabetic Retinopathy • Metabolic Disorders • Ophthalmology • Retinal Disorders • Type 2 Diabetes Mellitus • RBP4 • SPP1

Monotherapy Blood Pressure Response and Control-Rates in Treatment-Naïve Patients with Arterial Hypertension: A Randomized Comparison of Four Different Antihypertensive Drug Classes. (PubMed, Kidney Blood Press Res) - "Initial antihypertensive monotherapy failed in most patients (73% uncontrolled, 21%/18% at optimal treatment goal at TP1) even in low-risk patients, with efficacy varying by drug class (inhibitors of the renin-angiotensin-aldosterone system best, HCT least). These findings support guideline-recommended combination therapy."

Journal • Monotherapy • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension

Potential of Combination Pharmacotherapy in Patients with Arterial Hypertension and Prediabetes: Focus on Organ Protection. (PubMed, Kardiologiia) - "The combination including moxonidine was associated with a significant decrease in fasting plasma insulin that was more pronounced than with the diuretic treatment.Conclusion    In patients with AH and prediabetes, the combination therapy including perindopril, metformin and moxonidine provided a significant improvement in the structural and functional state of the LV myocardium and intrarenal vascular resistance comparable to the improvement produced by a combination of perindopril, metformin and sustained-release indapamide. The combination of an ACE inhibitor, biguanide and moxonidine may in some cases be a preferred pharmacotherapy option for patients with AH and early carbohydrate metabolism disorders due to the observed significant metabolic benefits."

Journal • Cardiovascular • Hypertension • Metabolic Disorders • Pulmonary Arterial Hypertension